Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Momelotinib (MMB)	8	214
Total, all-cause mortality	Ruxolitinib (RUX)	6	216
Total, all-cause mortality	MMB to MMB	44	171
Total, all-cause mortality	RUX to MMB	54	197
Total, other adverse events	Momelotinib (MMB)	197	214
Total, other adverse events	Ruxolitinib (RUX)	206	216
Total, other adverse events	MMB to MMB	153	171
Total, other adverse events	RUX to MMB	188	197
Total, serious adverse events	Momelotinib (MMB)	49	214
Total, serious adverse events	Ruxolitinib (RUX)	39	216
Total, serious adverse events	MMB to MMB	79	171
Total, serious adverse events	RUX to MMB	79	197

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01969838/event-totals